Unfortunately, this combination approach was effective only against p53 wild-type AML, whereas failed to kill AML cells carrying p53 mutation or deletion, a common and poor-prognostic genetic abnormality in this disease. The gene discussed is TP53; the disease is acute myeloid leukemia.